Dental Care Clinics in Kingwood, WV Accepting Medicare
5 Dental Care Clinics found. Showing 1 - 5
 Everett & Howell Dds Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 202 Tunnelton St, Suite 214, Kingwood, WV 26537 Phone: 304-329-1989 Fax: 304-329-2550 |
Gary G Naylor Dds Pllc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 202 Tunnelton St Ste 214, Kingwood, WV 26537 Phone: 304-329-1989 |
Kingwood Family Dental Dentist Medicare: Not Enrolled in Medicare Practice Location: 430 Morgantown St, Kingwood, WV 26537 Phone: 304-329-3142 Fax: 304-329-0700 |
Preston Dental Care Pllc Dentist Medicare: Not Enrolled in Medicare Practice Location: 202 Tunnelton St Ste 214, Kingwood, WV 26537 Phone: 304-329-1989 |
Les E. Nicholson D.d.s. Inc. Dentist Medicare: Not Enrolled in Medicare Practice Location: 112 E Court St, Kingwood, WV 26537 Phone: 304-329-1691 Fax: 304-329-3382 |
News Archive
New study: Two peptide agent combination might block tumor growth
A new study suggests that combining two experimental anticancer peptide agents might simultaneously block formation of new tumor blood vessels while also inhibiting the growth of tumor cells.
Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel
The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel. Such an added benefit cannot be derived from the dossier, however, as the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable.
New experimental device effectively removes blood clots in stroke patients
An experimental device for removing blood clots in stroke patients dramatically outperformed the standard mechanical treatment, according to research presented by UCLA Stroke Center director Dr. Jeffrey L. Saver at the American Stroke Association's 2012 international conference in New Orleans on Feb. 3.
Patient-reported outcomes linked to aromatase inhibitor adherence
If you want to predict which breast cancer patients will most likely stop taking aromatase inhibitors, check out their own responses to the health questions patients commonly answer in cancer clinical trials, according to research findings to be presented Friday, Dec. 13 at the San Antonio Breast Cancer Symposium.
› Verified 5 days ago